Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of combination of multiple serum tumor markers in specific early diagnosis and curative effect monitoring and detection of pancreatic cancer

A tumor marker and early diagnosis technology, applied in the field of medical detection, can solve the problems of poor specificity, increase, and increase of CA19-9, and achieve the effect of large clinical benefits

Pending Publication Date: 2022-03-22
引加(上海)生物医药科技有限公司 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional tumor marker CA19-9 is the only biomarker approved by the US Food and Drug Administration for the diagnosis of pancreatic cancer, but the specificity of CA19-9 is poor, and it is found in chronic pancreatitis, stem-negative jaundice and other cancers. rise
CA19-9 detection not achievable especially in patients with Lewis-negative phenotype
Traditional CEA tumor markers are non-organ-specific indicators that are elevated in patients with other tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of multiple serum tumor markers in specific early diagnosis and curative effect monitoring and detection of pancreatic cancer
  • Application of combination of multiple serum tumor markers in specific early diagnosis and curative effect monitoring and detection of pancreatic cancer
  • Application of combination of multiple serum tumor markers in specific early diagnosis and curative effect monitoring and detection of pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1: preparation kit of the present invention

[0041] The main components and preparation of the kit of the present invention:

[0042] R1 reagent:

[0043] Fluorescein isothiocyanate (FITC)-labeled anti-MMP-II antibody, antibody concentration range 0.5-2.5μg / mL, bovine serum albumin and preservative Tris buffer (concentration 0.1mol / L, pH=8.0).

[0044] Fluorescein isothiocyanate (FITC)-labeled anti-MIC-1 antibody, antibody concentration range 0.2-1.2μg / mL, bovine serum albumin and preservative Tris buffer (concentration 0.1mol / L, pH=8.0).

[0045] Fluorescein isothiocyanate (FITC)-labeled anti-REG4 antibody, antibody concentration range 0.2-1.2μg / mL, bovine serum albumin and preservative Tris buffer (concentration 0.1mol / L, pH=8.0).

[0046]Fluorescein isothiocyanate (FITC)-labeled anti-LAMC2 antibody, antibody concentration range 0.5-1.5μg / mL, bovine serum albumin and preservative Tris buffer (concentration 0.1mol / L, pH=8.0)1) Fluorescein thiocyanate (FI...

Embodiment 2

[0103] Embodiment 2: the detection method of embodiment 1 kit

[0104] The patent kit adopts magnetic particle chemiluminescence immunoassay method, and is suitable for automatic magnetic particle chemiluminescence analyzer. The detection principle is to mix and incubate the sample to be tested, reagent 1 (R1), and reagent 2 (R2), and a pair of antibodies labeled with fluorescein isothiocyanate (FITC) in R1 and alkaline phosphatase (ALP) in R2 The biomarker monoclonal antibody specifically binds to the biomarker antigen molecule in the sample to form an immune complex. The immune complex and the magnetic separation reagent (M) are mixed and incubated, and the immune complex is further captured by the anti-FITC antibody coupled on the surface of the magnetic particle and adsorbed to the surface of the magnetic particle. After washing and removing unbound antibodies and impurities, a luminescent substrate is added, ALP catalyzes the substrate to emit light, and the relative lum...

Embodiment 3

[0113] Example 3: When the kit of the present invention detects serum samples from healthy people, patients with chronic pancreatitis-related diseases, pancreatic cancer, and other malignant tumors of the digestive tract, the sensitivity, specificity and ROC curve analysis of the performance indicators of the kit sample.

[0114] The clinical samples included in this patent come from the remaining serum samples after clinical tests of inpatients or outpatients in the Cancer Hospital of the Chinese Academy of Medical Sciences, Henan Provincial People's Hospital, Qingdao Municipal Hospital and other hospitals. The sample volume is 200ul ~ 500ul, and the sample- 80 ℃ w storage time 2 to 3 years. The case information of each sample is complete, clear and traceable. The distribution information of the sample population is as follows:

[0115]

[0116] Optimal combination of multi-index combined detection in early diagnosis of pancreatic cancer:

[0117] Surgical resection is ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of combination of multiple serum tumor markers in specific early diagnosis and curative effect monitoring and detection of pancreatic cancer, and particularly relates to the technical field of medical detection, in particular to combined detection of multiple serological indexes. The invention relates to an in-vitro detection kit and a detection method for assisting early specific diagnosis, curative effect monitoring and prognostic evaluation of pancreatic cancer in clinical medical detection. According to the invention, the indexes comprise a plurality of multi-index combinations of MMPII, MIC-1, REG4, LAMC2, OPN, GPC-1, CA19-9 and CEA. The defects of low inspiration and specificity of single-index or combined detection in the current pancreatic cancer clinical medicine detection are effectively overcome through optimal index and multi-index combined detection. The method provides a new method for early diagnosis and curative effect monitoring and detection of pancreatic cancer, and is used for realizing early diagnosis and early treatment of pancreatic cancer, improving diagnosis and treatment efficiency and perfecting prognostic evaluation.

Description

technical field [0001] The present invention relates to the technical field of medical detection, and more specifically, the present invention relates to the combined application of various serum tumor markers in specific early diagnosis and curative effect monitoring detection of pancreatic cancer. Background technique [0002] Pancreatic cancer is a malignant tumor that is difficult to detect early, has a poor prognosis, and has an morbidity close to mortality. In China, the 5-year survival rate of pancreatic cancer patients has gradually decreased from 11.7% in 2003 to 7.2% in 2015, the lowest among all cancers. Pancreatic cancer ranks fourth among cancers with a high mortality rate in the United States and Europe, and the 5-year overall survival rate is only 9.3%, and it is expected to rise to the second place by 2030. Clinically, pancreatic cancer is mainly diagnosed by physical methods, including ultrasonography, magnetic resonance imaging, and endoscopic ultrasonogra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/573G01N33/543G01N33/58
CPCG01N33/57438G01N33/57488G01N33/573G01N33/57473G01N33/582G01N33/581G01N33/54326G01N2333/96494G01N2333/78G01N2333/475G01N2333/52G01N2333/4722G01N2333/47
Inventor 喻长杰李长泽杨冰冰孙茜薛颖
Owner 引加(上海)生物医药科技有限公司